Atrial Fibrillation Therapy and HeartFailure Hospitalization in AdultsWith Tetralogy of Fallot.

Abstract

This study hypothesized that atrial fibrillation was associated with heart failure (HF) hospitalization, and that patients who received rhythm control therapy had a lower incidence of HF hospitalization and mortality. Atrial fibrillation is a known risk factor for HF hospitalization and mortality in patients with acquired heart disease. Although atrial arrhythmias are common in adults with tetralogy of Fallot (TOF), data about prevalence and outcomes of therapy for atrial fibrillation are very limited. The MACHD (Mayo Adult Congenital Heart Disease) database was queried for adults with repaired TOF and documented atrial fibrillation from 1990 to 2017. Primary endpoint was HF hospitalization defined as admission for volume overload (pulmonary congestion and/or peripheral edema) requiring intravenous diuretics. Secondary endpoint was the effect of rhythm control therapy on HF hospitalization and all-cause mortality. Patients were divided into rhythm control and rate control groups based on the therapy initiated at the time of arrhythmia diagnosis. Of 415 patients, 27 (7%) had 42 HF hospitalizations. Of these 415 patients, 88 (21%) had atrial fibrillation at age 49 ± 13 years. Atrial fibrillation was an independent risk factor for HF hospitalization (adjusted hazard ratio: 2.67; 95% confidence interval: 1.04 to 7.34; p= 0.045). The 88 patients were divided into the rhythm control group (n= 61, 69%) and the rate control group (n= 27, 31%). The rate control group had higher unadjusted annual incidence of HF hospitalization (13% vs. 3%; p= 0.001) and all-cause mortality (11% vs. 4%; p= 0.002). Atrial fibrillation was a risk factor for HF hospitalization and mortality in TOF patients, and rhythmcontrol therapy was protective against these adverse events.